78 related articles for article (PubMed ID: 17124426)
1. Peroxisome proliferator-activated receptor-gamma agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution.
Yao Q; Pawlaczyk K; Ayala ER; Kuzlan M; Styszynski A; Breborowicz A; Heimburger O; Qian J; Stenvinkel P; Axelsson J; Lindholm B
Blood Purif; 2006; 24(5-6):575-82. PubMed ID: 17124426
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model.
Bozkurt D; Taskin H; Sezak M; Biçak S; Sen S; Ok E; Duman S
Adv Perit Dial; 2008; 24():32-8. PubMed ID: 18985998
[TBL] [Abstract][Full Text] [Related]
3. Role of rosiglitazone in lipopolysaccharide-induced peritonitis: a rat peritoneal dialysis model.
Song SH; Kwak IS; Yang BY; Lee DW; Lee SB; Lee MY
Nephrology (Carlton); 2009 Apr; 14(2):155-63. PubMed ID: 19207869
[TBL] [Abstract][Full Text] [Related]
4. The role of the TGF/Smad signaling pathway in peritoneal fibrosis induced by peritoneal dialysis solutions.
Yao Q; Pawlaczyk K; Ayala ER; Styszynski A; Breborowicz A; Heimburger O; Qian JQ; Stenvinkel P; Lindholm B; Axelsson J
Nephron Exp Nephrol; 2008; 109(2):e71-8. PubMed ID: 18600031
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor.
Aroeira LS; Aguilera A; Selgas R; Ramírez-Huesca M; Pérez-Lozano ML; Cirugeda A; Bajo MA; del Peso G; Sánchez-Tomero JA; Jiménez-Heffernan JA; López-Cabrera M
Am J Kidney Dis; 2005 Nov; 46(5):938-48. PubMed ID: 16253736
[TBL] [Abstract][Full Text] [Related]
6. PPAR-γ agonist rosiglitazone ameliorates peritoneal deterioration in peritoneal dialysis rats with LPS-induced peritonitis through up-regulation of AQP-1 and ZO-1.
Zhang Y; Feng J; Wang Q; Zhao S; Xu J; Li H
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29871973
[TBL] [Abstract][Full Text] [Related]
7. Effects of new peritoneal dialysis solutions, pyridoxamine and AT1 receptor blocker, on TGF-beta1 and VEGF expression in rat peritoneal mesothelial cells.
Mizuiri S; Ohashi Y; Hemmi H; Arita M; Yamada K; Aoki T; Miyagi M; Sakai K; Aikawa A
Am J Nephrol; 2009; 30(3):295-302. PubMed ID: 19546527
[TBL] [Abstract][Full Text] [Related]
8. Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells.
Peng Y; Liu H; Liu F; Liu Y; Li J; Chen X
Nephrology (Carlton); 2006 Dec; 11(6):516-23. PubMed ID: 17199790
[TBL] [Abstract][Full Text] [Related]
9. Preservation of peritoneal morphology and function by pentoxifylline in a rat model of peritoneal dialysis: molecular studies.
Hung KY; Huang JW; Chiang CK; Tsai TJ
Nephrol Dial Transplant; 2008 Dec; 23(12):3831-40. PubMed ID: 18614818
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
[TBL] [Abstract][Full Text] [Related]
11. PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage.
Sandoval P; Loureiro J; González-Mateo G; Pérez-Lozano ML; Maldonado-Rodríguez A; Sánchez-Tomero JA; Mendoza L; Santamaría B; Ortiz A; Ruíz-Ortega M; Selgas R; Martín P; Sánchez-Madrid F; Aguilera A; López-Cabrera M
Lab Invest; 2010 Oct; 90(10):1517-32. PubMed ID: 20531289
[TBL] [Abstract][Full Text] [Related]
12. A combination of a PPAR-gamma agonist and an angiotensin II receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells.
Yao Q; Ayala ER; Qian JQ; Stenvinkel P; Axelsson J; Lindholm B
Clin Nephrol; 2007 Nov; 68(5):295-301. PubMed ID: 18044261
[TBL] [Abstract][Full Text] [Related]
13. Effects of low glucose degradation products peritoneal dialysis fluid on the peritoneal fibrosis and vascularization in a chronic rat model.
Kim CD; Kwon HM; Park SH; Oh EJ; Kim MH; Choi SY; Choi MJ; Kim IS; Park MS; Kim YJ; Kim YL
Ther Apher Dial; 2007 Feb; 11(1):56-64. PubMed ID: 17309576
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats.
Sánchez-Hidalgo M; Martín AR; Villegas I; de la Lastra CA
Eur J Pharmacol; 2007 May; 562(3):247-58. PubMed ID: 17343846
[TBL] [Abstract][Full Text] [Related]
15. The effect of oxidative stress inhibition with trimetazidine on the peritoneal alterations induced by hypertonic peritoneal dialysis solution.
Günal AI; Celiker H; Ustundag B; Akpolat N; Dogukan A; Akcicek F
J Nephrol; 2003; 16(2):225-30. PubMed ID: 12768069
[TBL] [Abstract][Full Text] [Related]
16. BMP-7 blocks mesenchymal conversion of mesothelial cells and prevents peritoneal damage induced by dialysis fluid exposure.
Loureiro J; Schilte M; Aguilera A; Albar-Vizcaíno P; Ramírez-Huesca M; Pérez-Lozano ML; González-Mateo G; Aroeira LS; Selgas R; Mendoza L; Ortiz A; Ruíz-Ortega M; van den Born J; Beelen RH; López-Cabrera M
Nephrol Dial Transplant; 2010 Apr; 25(4):1098-108. PubMed ID: 20067910
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 and vascular endothelial growth factor expressions are involved in ultrafiltration failure.
Guo J; Xiao J; Gao H; Jin Y; Zhao Z; Jiao W; Liu Z; Zhao Z
J Surg Res; 2014 May; 188(2):527-536.e2. PubMed ID: 24559584
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum.
Duman S; Wieczorowska-Tobis K; Styszynski A; Kwiatkowska B; Breborowicz A; Oreopoulos DG
Adv Perit Dial; 2004; 20():31-6. PubMed ID: 15384791
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia.
Liu D; Zeng BX; Zhang SH; Yao SL
Inflamm Res; 2005 Nov; 54(11):464-70. PubMed ID: 16307220
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the biocompatibility of phosphate-buffered saline and dianeal 3.86% in the rat model of peritoneal dialysis.
Wieczorowska-Tobis K; Polubinska A; Breborowicz A; Oreopoulos DG
Adv Perit Dial; 2001; 17():42-6. PubMed ID: 11510294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
